Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial

被引：0

作者：

Dodick, D. ^{[1
]}

Nahas, S. ^{[2
]}

Pozo-Rosich, P. ^{[3
,4
]}

Bilchik, T. ^{[5
]}

McAllister, P. ^{[6
]}

Finnegan, M. ^{[7
]}

Ma, J. ^{[7
]}

Chalermpalanupap, T. ^{[7
]}

Dabruzzo, B. ^{[7
]}

Lipton, R. ^{[8
]}

机构：

[1] Mayo Clin, Scottsdale, AZ USA

[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Autonomous Univ Barcelona, Barcelona, Spain

[5] Yale Sch Med, New Haven, CT USA

[6] New England Inst Neurol & Headache, Stamford, CT USA

[7] AbbVie, Madison, NJ USA

[8] Albert Einstein Coll Med, Bronx, NY 10467 USA

来源：

JOURNAL OF HEADACHE AND PAIN | 2022年 / 23卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P110

引用

页数：2

共 50 条

[21] Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study
Mysler, Eduardo
Tanaka, Yoshiya
Kavanaugh, Arthur
Aletaha, Daniel
Taylor, Peter
Song, In-Ho
Shaw, Tim
Song, Yanna
DeMasi, Ryan
Ali, Mira
Fleischmann, Roy
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[22] IMPACT OF UPADACITINIB OR ADALIMUMAB AS INITIAL THERAPY ON THE ACHIEVEMENT OF 48-WEEK TREATMENT GOALS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: POST HOC ANALYSIS OF A PHASE 3 STUDY
Mysler, E.
Tanaka, Y.
Kavanaugh, A.
Aletaha, D.
Taylor, P. C.
Song, I. H.
Shaw, T.
Song, Y.
Demasi, R.
Ali, M.
Fleischmann, R.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 566 - 567
[23] Responder Rates to Atogepant in Patients with Episodic Migraine: A Post Hoc Analysis of Results from a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
Dodick, D. W.
Ailani, J.
Goadsby, P. J.
Trugman, J. M.
Finnegan, M.
Lakkis, H.
Li, Y.
Szegedi, A.
HEADACHE, 2019, 59 : 79 - 80
[24] Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
Lipton, Richard B.
Tepper, Stewart J.
Silberstein, Stephen D.
Kudrow, David
Ashina, Messoud
Reuter, Uwe
Dodick, David W.
Zhang, Feng
Rippon, Gregory A.
Cheng, Sunfa
Mikol, Daniel D.
CEPHALALGIA, 2021, 41 (01) : 6 - 16
[25] Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials
Schim, Jack D.
Anderson, Carlton
Brunner, Elizabeth
Hirman, Joe
Ogbru, Annette
Cady, Roger
McGill, Lora
HEADACHE, 2022, 62 (05): : 558 - 565
[26] Effect of Atogepant on the Activity Impairment in Migraine-Diary and Work Productivity and Activity Impairment Questionnaire in a 12-Week, Double-blind, Randomized, Phase 3 (PROGRESS) Trial for Preventive Treatment of Chronic Migraine
Lipton, R.
Pozo-Rosich, P.
Dodick, D.
Friedman, D.
Ailani, J.
Smith, J.
Stokes, J.
Schwefel, B.
Gandhi, P.
HEADACHE, 2023, 63 : 127 - 128
[27] Effect of Atogepant on the Activity Impairment in Migraine-Diary and Work Productivity and Activity Impairment Questionnaire in a 12-Week, Double-blind, Randomized, Phase 3 (PROGRESS) Trial for Preventive Treatment of Chronic Migraine
Lipton, Richard B.
Pozo-Rosich, Patricia
Dodick, David W.
Friedman, Deborah I.
Ailani, Jessica
Smith, Jonathan H.
Stokes, Jonathan
Schwefel, Brittany
Gandhi, Pranav
CEPHALALGIA, 2022, 42 (1_SUPPL) : 65 - 67
[28] Effect of atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-week, doubleblind, randomized, phase 3 (PROGRESS) trial for preventive treatment of chronic migraine (CM)
Lipton, R.
Pozo-Rosich, P.
Dodick, D.
Christie, S.
Ailani, J.
Nagy, K.
Stokes, J.
Guo, H.
Gandhi, P.
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
[29] Effect of Atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-Week, Double-blind, Randomized, Phase 3 (PROGRESS) Trial for Preventive Treatment of Chronic Migraine
Lipton, Richard B.
Pozo-Rosich, Patricia
Dodick, David W.
Christie, Suzanne
Ailani, Jessica
Nagy, Krisztian
Stokes, Jonathan
Guo, Hua
Gandhi, Pranav
CEPHALALGIA, 2022, 42 (1_SUPPL) : 87 - 89
[30] Effect of Atogepant on Migraine-Specific Quality of Life Questionnaire and Headache Impact Test-6 in a 12-Week, Double-blind, Randomized, Phase 3 ( PROGRESS) Trial for Preventive Treatment of Chronic Migraine
Lipton, R.
Pozo-Rosich, P.
Dodick, D.
Christie, S.
Ailani, J.
Nagy, K.
Stokes, J.
Guo, H.
Gandhi, P.
HEADACHE, 2023, 63 : 126 - 127

← 1 2 3 4 5 →